Markets

Cancer Genetics postpones $18 million IPO

Cancer Genetics, which offers personalized genomic tests to improve the diagnosis and treatment of cancer, postponed its IPO on Tuesday, citing poor market conditions. The Rutherford, NJ-based company was founded in 1999 and booked $4 million in sales for the year ended 12/31/2012. Aegis Capital was set to be the sole bookrunner on the deal.

This was the diagnostics company's third postponement. Cancer Genetics previously attempted to price in May 2012 ($48 million deal size) and February 2013 ($35 million deal size).

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

VYNT

Other Topics

IPOs

Latest Markets Videos

Renaissance Capital

Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

Learn More